COVID Treatment: CCRS to study on prophylactic use of Siddha
About 60 asymptomatic, mild and moderate coronavirus positive patients would be taken up for the study at the COVID-19 Care Centre established by Greater Chennai Corporation at Vysarpadi
Chennai - With a Siddha 'add-on' therapy to allopathic treatment at a government COVID-19 care center here giving encouraging results, the Central Council for Research in Siddha (CCRS) will soon commence a study on 60 coronavirus patients at Vysarpadi in the city.
The new clinical trial aims to bring out the efficacy of the Siddha group of medicines and 'Kabasura kudineer' as prophylactic designed to treat or prevent COVID-19. The add-on therapy was earlier attempted at the COVID-19 care center at the Government Stanley Medical College Hospital.
Read Also: Tamil Nadu vouches for traditional Siddha treatment to battle COVID outbreak
Kabasura kudineer is a herbal concoction, comprising dry ingredients of ginger, pippali, clove, cirukancori root and many other herbs.
"We are awaiting the number from the Clinical Trials Registry-India (CTRI) to begin the trial next week," Dr K Kanakavalli, director-general of CCRS, said. CCRS is the apex body pertaining to research in the Siddha system of medicine.
It works towards the scientific validation of the Siddha system of medicine through clinical research, drug research, medicinal plants research, fundamental research, literary research, and documentation. The new study is in sync with the directive issued by the Union Ayush Ministry and with consent from the Tamil Nadu government.
"About 60 asymptomatic, mild and moderate coronavirus positive patients would be taken up for the study at the COVID-19 Care Centre established by Greater Chennai Corporation at Vysarpadi," she told PTI on Monday. "Siddha, which was recently tried at Stanley GH as add-on therapy on 30 positive patients, proved successful and based on the outcome we have decided to take up the new study," she said.
Earlier, the Siddha Central Research Institute (SCRI) here conducted a prophylactic study on 15,000 mild or moderate coronavirus patients and those who were asymptomatic. A similar study is on at the SCRI units at Bengaluru, Delhi, Tirupati, Palayamkottai and Puducherry. These studies are aimed at evaluating Kabasura kudineer as drug of choice.
Recently, a retrospective study on the herbal concoction and group of Siddha medicines was conducted in Coimbatore.
Read Also: Biocon, DKSH ink pact to commercialize 7 generic formulations in Singapore, Thailand
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.